Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | PRKCA | P17252 | 5/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958966 | 1.00 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL369749 | 1.00 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL367858 | 1.00 | MAPT (0.62) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL369084 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL371296 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL371275 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL26602804 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL369798 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL369784 | 0.91 | PRKCA (0.60) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL371177 | 0.88 | MAPT (0.55) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | claimed |
| US-20160339041-A1 | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE | TROPHOS (FR) | 2016-11-24 | — | — | US | claimed |
| US-20150079155-A1 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood | BIONEER A/S (DK) | 2015-03-19 | — | — | US | claimed |
| WO-2015036044-A1 | CATIONIC LIPID VEHICLES FOR DELIVERY OF TLR7 AGONISTS FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | TELORMEDIX SA (CH) | 2015-03-19 | — | — | WO | claimed |
| US-20150056269-A1 | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE | TROPHOS (FR) | 2015-02-26 | — | — | US | claimed |
| EP-2825158-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | Bioneer A/S (DK) | 2015-01-21 | — | — | EP | claimed |
| WO-2013135800-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | BIONEER A/S (DK) | 2013-09-19 | — | — | WO | claimed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | claimed |
| EP-1045698-B1 | PATIENT-SPECIFIC WHITE BLOOD CELL MALIGNANCY VACCINE FROM MEMBRANE-PROTEOLIPOSOMES | BIOMIRA USA INC (US) | 2006-06-07 | — | — | EP | claimed |
| US-20020155135-A1 | Method of making patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes | BIOMIRA U.S.A., INC. | 2002-10-24 | — | — | US | claimed |
| US-20010012517-A1 | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes | POPESCU MIRCEA C (US) | 2001-08-09 | — | — | US | claimed |
| US-6207170-B1 | EXTRACT FROM PLASMA MEMBRANE FORM MALIGNANT WHITE BLOOD CELLS | BIOMIRA U.S.A., INC. | 2001-03-27 | — | — | US | claimed |
| EP-1045698-A1 | PATIENT-SPECIFIC WHITE BLOOD CELL MALIGNANCY VACCINE FROM MEMBRANE-PROTEOLIPOSOMES | BIOMIRA USA INC. (US) | 2000-10-25 | — | — | EP | claimed |
| WO-1999036085-A1 | PATIENT-SPECIFIC WHITE BLOOD CELL MALIGNANCY VACCINE FROM MEMBRANE-PROTEOLIPOSOMES | BIOMIRA USA INC. (US) | 1999-07-22 | — | — | WO | claimed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117940563-A | Improved small RNA purification process | 米尔纳格林有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4134432-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2023-02-15 | — | — | EP | disclosed |
| EP-1045698-A1 | PATIENT-SPECIFIC WHITE BLOOD CELL MALIGNANCY VACCINE FROM MEMBRANE-PROTEOLIPOSOMES | BIOMIRA USA INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999038493-A1 | MICROPARTICLE INHALATION FORMULATIONS | RTP PHARMA INC. (CA) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999036085-A1 | PATIENT-SPECIFIC WHITE BLOOD CELL MALIGNANCY VACCINE FROM MEMBRANE-PROTEOLIPOSOMES | BIOMIRA USA INC. (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339041-A1 | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE | LIPA, NPC1L1, CETP | MAPT 2416/4885MAPK1 4311/4885LMNA 738/4885 |
| US-20150056269-A1 | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE | LIPA, NPC1L1, CETP | MAPT 2416/4885MAPK1 4311/4885LMNA 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.